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Abstract 169 
Background & Aims: Agents are being developed for treatment of eosinophilic esophagitis 170 
(EoE).  However, it is not clear what outcome measures would best determine the efficacy and 171 
safety of these agents in clinical trials. We performed a systematic review of outcomes used in 172 
randomized placebo-controlled trials of EoE and we estimate the placebo response and rates of 173 
remission. 174 
 175 
Methods: We searched MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, and the EU Clinical 176 
Trials Register from inception through February 20, 2018 for randomized controlled trials of 177 
pharmacologic therapies for EoE. Efficacy outcome definitions, measurement tools, and the 178 
proportion of patients responding to placebo were collected and stratified by based on 179 
histologic, endoscopic, and patient-reported outcomes. 180 
 181 
Results: We analyzed data from 22 placebo-controlled trials, comprising 1112 patients with 182 
EoE. Ten additional active registered trials were identified. Most published trials evaluated 183 
topical corticosteroid therapy (13/22, 59.1%). Histologic outcomes measuring eosinophil density 184 
and patient-reported outcomes were reported in 21/22 published trials (95.5%). No consistently 185 
applied definitions of histologic or patient-reported response or remission were identified. 186 
Endoscopic outcomes were described in 60% (12/20) of published trials. The EoE Endoscopic 187 
Reference Score is the most commonly applied tool for describing changes in endoscopic 188 
appearance. The median histologic response to placebo was 3.7% (range 0%-31.6%) and the 189 
median rate of remission in patients given placebo was 0.0% (range 0%-11.0%). The median 190 
patient-reported response to placebo was 14.4% (range 8.6%-77.8%) and rate of remission in 191 
patients given placebo was 26.2% (range 13.2%-35.7%). 192 
 193 
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Conclusions: In a systematic review of the literature, we found that no standardized definitions 194 
of histologic, endoscopic, or patient-reported outcomes are used to determine whether 195 
pharmacologic agents produce a response or remission in patients with EoE. A core outcome 196 
set is needed to reduce heterogeneity in outcome reporting and facilitate trial interpretation and 197 
comparison of results from trials. 198 
 199 
Keywords:  200 
esophagus, inflammation, drug, endoscopy, histology 201 
202 
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Background & Aims 203 
Eosinophilic esophagitis (EoE) is a chronic inflammatory condition characterized histologically 204 
by eosinophilic infiltration and clinically by symptoms of esophageal dysfunction in the context of 205 
an antigen-mediated immune response.1 Consensus guidelines have established first-line 206 
pharmacologic, dietary, and endoscopic treatment for EoE, emphasizing the role of topical 207 
corticosteroids, dietary restriction, and endoscopic dilation targeted at improving patient 208 
symptoms and reducing histologic eosinophil burden.2, 3 Topical corticosteroids are the mainstay 209 
of drug-based therapy, but there are no US Food and Drug Administration (FDA)-approved 210 
treatments and only one orodispersible budesonide formulation has been approved by the 211 
European Medicines Agency (EMA) for treatment of EoE.4, 5 Accordingly, there is great interest 212 
in therapeutic development in this field with multiple classes of agents under evaluation. 213 
 214 
Several barriers to efficient drug development in EoE exist.6 Importantly, there is a lack of 215 
standardized outcome measures for use in registration trials that can support labelling claims. 216 
The FDA mandates that “clinically meaningful” endpoints that measure the way patients feel, 217 
function, and survive be used.7 Therefore, analogous to randomised controlled trials (RCTs) in 218 
inflammatory bowel disease (IBD), future EoE clinical trials are likely to incorporate coprimary 219 
endpoints featuring both patient-reported outcomes (PROs) and objective inflammatory 220 
measures. Nevertheless, there is uncertainty regarding the appropriateness of endpoint 221 
definitions and the responsiveness of current disease activity indices in EoE8 and unsurprisingly, 222 
there is lack of consensus on the type of outcomes to measure, the way these outcomes should 223 
be defined, and the circumstances in which these outcomes should be assessed.9 224 
 225 
Developing a core outcome set (COS) is thus a priority in EoE research. A COS is a consensus-226 
derived minimum set of outcomes that should be measured and reported in all clinical trials in a 227 
given field.10 Adoption of a COS minimizes heterogeneity in reporting and potential publication 228 
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bias, improves the quality of evidence synthesis, and facilitates comparisons of interventions in 229 
meta-analyses. COS development is a multi-step process that involves systematically reviewing 230 
the literature to identify current trial endpoints, surveying affected stakeholders, and achieving 231 
consensus.10 A similar COS development initiative is underway in IBD.11, 12 In addition to 232 
selecting appropriate endpoints, understanding the placebo response in clinical trials is critical 233 
for efficient drug development. Furthermore, this process facilitates accurate sample size 234 
calculations and maximizes assay sensitivity for detecting true differences between active 235 
comparator and placebo. Whilst placebo rates in other gastrointestinal disorders have been well 236 
characterized,13-15 placebo rates and the determinants of the placebo response in EoE RCTs 237 
require further evaluation. Hirano et al. have previously demonstrated in a phase 2 trial of 238 
budesonide oral suspension that despite a placebo run-in period, symptom improvement 239 
occurred in approximately one quarter of patients randomised to placebo with no baseline 240 
demographic features predictive of this response.16 241 
 242 
To address these limitations, we systematically reviewed all randomised, placebo-controlled 243 
RCTs of pharmacologic interventions in EoE. We aim to describe placebo rates in EoE trials, 244 
identify relevant endpoints and outcome definitions used in current EoE trials, and establish a 245 
conceptual framework by which a COS for future EoE trials can be developed. 246 
247 
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Methods 248 
Search Strategy 249 
MEDLINE (Ovid, 1948-2017), Embase (Ovid, 1947-2017), and CENTRAL (1994-2017) were 250 
searched without language restriction from inception to February 20, 2018 for RCTs of 251 
pharmacologic interventions in EoE. Using the PICO framework, we aimed to capture all studies 252 
enrolling patients with EoE regardless of age (patient population), undergoing pharmacologic 253 
therapy (intervention), compared against placebo (comparator), and describing any symptom-254 
based, endoscopic, histologic, or exploratory outcomes (outcome). The search strategy is 255 
outlined in Supplemental File 1. Conference proceedings from Digestive Disease Week and 256 
United European Gastroenterology Week (2012-2017) and references of relevant studies and 257 
review articles were hand-searched to identify additional studies. Finally, ClinicalTrials.gov and 258 
the European Union (EU) Clinical Trials Register were searched for registered, actively 259 
recruiting RCTs. Citations and abstracts were screened and complete manuscripts were 260 
retrieved for potentially eligible studies. Articles were independently assessed by two 261 
investigators (TMN, BvR) and disagreement was resolved by consensus and discussion with a 262 
third reviewer (CM). All data were extracted independently and accuracy was verified in a 263 
quality control process by a third investigator (CEP). 264 
 265 
Study Eligibility Criteria 266 
Studies were eligible for inclusion if they reported a randomised, placebo-controlled trial in 267 
patients with EoE that evaluated a pharmacologic intervention. Similar criteria were applied to 268 
registered trials on ClinicalTrials.gov and the EU Clinical Trials Register. Studies of children, 269 
adolescents, or adults were eligible. However, trials of endoscopic dilation or dietary exclusion 270 
therapies, and trials without a placebo comparator arm were excluded. These restrictions were 271 
applied to focus this review on pharmacologic interventions, although we recognize that similar 272 
challenges with respect to minimizing placebo response and outcome heterogeneity apply to 273 
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trials of dietary or endoscopic therapy and non-placebo controlled studies. Separately published 274 
post-hoc or retrospective analyses of RCTs were not included to avoid duplicate inclusion. 275 
 276 
Data Extraction 277 
The primary data extraction included: (1) descriptions of primary and secondary efficacy 278 
outcomes, definitions, and measurement tools; (2) descriptions of exploratory outcomes; and (3) 279 
the proportion of patients randomised to placebo achieving patient-reported, endoscopic, or 280 
histologic response and remission (as defined by the original study authors). Additionally, 281 
information regarding trial design (publication year, trial phase, number of treatment arms, trial 282 
location and number of trial centres, total participants and participants randomised to placebo, 283 
follow-up duration), trial-level patient data (age and gender distribution, proportion on proton 284 
pump inhibitor (PPI) therapy at baseline, disease duration), and the active comparator (drug 285 
class and route of administration) were collected. 286 
 287 
The risk of bias in the published studies was assessed using the Cochrane risk of bias tool, 288 
which assesses the following domains: 1) selection bias (random sequence generation, 289 
allocation concealment); 2) performance bias (blinding of participants and personnel); 3) 290 
detection bias (blinding of outcome assessment); 4) attrition bias (incomplete outcome data); 5) 291 
reporting bias (selective reporting); and 6) other sources of bias.17 292 
 293 
Data Synthesis and Analysis 294 
Standard descriptive statistics were used to describe trial characteristics. A comprehensive 295 
inventory of outcomes and definitions was generated through qualitative review and 296 
subsequently organized into subdomains (histology, endoscopy, patient-reported outcomes). 297 
The proportion of studies reporting each outcome was calculated and stratified by year of 298 
publication. 299 
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 300 
In the initial study protocol, we planned to pool histologic, endoscopic, and patient-reported 301 
placebo response and remission rates in meta-analysis using a random-effects model; however, 302 
due to the small number of trials and significant heterogeneity in outcome definitions, it was 303 
methodologically inappropriate to formally pool reported placebo rates. Additionally, a 304 
substantial proportion of trials reported placebo rates of 0% (see Results); pooling these 305 
studies in meta-analysis, even with a continuity factor, would likely result in biased estimates. 306 
Therefore, we generated a descriptive summary of the proportion of placebo responders or 307 
remitters where available but without pooled point estimates. For studies reporting quantitative 308 
before and after treatment changes in the mean or median scoring index, the percentage 309 
change in the placebo group was calculated by dividing the difference in quantitative score after 310 
treatment by the scale of the scoring instrument. The median and interquartile range of placebo 311 
response and remission rates was calculated and then graphically depicted in box-and-whisker, 312 
stratified by outcome domain. All statistical analyses were conducted using STATA 14.2 313 
(StataCorp, College Station, TX: StataCorp LP). 314 
 315 
This meta-analysis conforms to the Preferred Reporting Items for Systematic Reviews and 316 
Meta-Analyses (PRISMA) recommendations.18 317 
318 
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Results 319 
Search Results and Study Characteristics 320 
The flow diagram for inclusion of trials identified by the literature search is illustrated in 321 
Supplemental Figure 1. Twenty-two placebo-controlled RCTs19-40 were identified; another ten 322 
registered and enrolling trials were identified through ClinicalTrials.gov and the EU Clinical 323 
Trials Register. Baseline study characteristics are summarized in Table 1. Most of the published 324 
trials were phase II studies (81.8%, 18/22), enrolling adult patients (54.5%, 12/22). Thirteen 325 
studies (59.1%, 13/22) compared a corticosteroid preparation against placebo. Ten trials 326 
reported concomitant PPI use; the mean proportion of EoE patients receiving concomitant PPI 327 
therapy was 57.0% (standard deviation ±26.5%, range 13.2%-100%). The mean follow-up 328 
duration was 12.1 weeks (SD ±10.7 weeks, range 2-50 weeks). Risk of bias assessment is 329 
summarized in Supplemental Table 1; most studies were judged to be at low risk of bias for 330 
most domains. 331 
 332 
Outcome Reporting 333 
The proportion of trials reporting histologic, endoscopic, and patient-reported outcomes is 334 
summarized in Figure 1, stratified by year of publication. Both histologic and patient-reported 335 
outcomes were described in nearly all reported trials (95.5%, 21/22) and registered studies 336 
(90%, 9/10). In contrast, only 13 reported RCTs (59.1%) and four (40%) registered trials defined 337 
a priori endoscopic endpoints. Exploratory outcomes were evaluated in 68.2% (15/22) of 338 
reported RCTs and included: (1) serum or tissue biomarkers (including MIB-1/Ki-6719, 339 
interleukin (IL)-522, 25, IL1325, 27, 35, eotaxin22, 30, tryptase for mast cells19, 21, 23, 25, 27, 29, tumor 340 
necrosis factor21, 22, tenascin C21, 27, cytokeratin21, 23, terminal deoxynucleotidyl transferase-341 
mediated deoxyuridine triphosphate nick-end labeling positive inflammatory and epithelial 342 
cells21, 23, transforming growth factor beta (TGF-β)20-23, 25, 27, CD3/819, 21-23, eosinophil cationic 343 
protein21-23, eosinophil derived neurotoxin22, 24, eosinophil peroxidase27, serum 344 
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immunoglobulins29, and thymic stromal lymphopoietin35); (2) esophageal thickness23 (as 345 
measured on endoscopic ultrasound); (3) genetic factors associated with EoE (including single 346 
nucleotide polymorphisms of TGF-β20 and measures of the EoE transcriptome28, 30), and (4) 347 
esophageal distensibility measures as assessed by functional lumen imaging probe (FLIP).38 348 
 349 
Histology Outcome Definitions 350 
Definitions of histology outcomes for reported RCTs are summarized in Table 2 and for 351 
registered RCTs in Table 3. Most trials defined histology outcomes using eosinophil density as 352 
defined most commonly by peak eosinophil counts although no consistent thresholds for 353 
defining histologic response or remission were used. Furthermore, the definition of peak 354 
eosinophil count varied depending on field size, number of HPFs evaluated, and from which 355 
level of the esophagus samples were obtained. For histologic remission, peak eosinophil 356 
thresholds ranged from 0 to 6 eosinophils/high power field (HPF); for histologic response, peak 357 
eosinophil count thresholds ranged from 5 to 24 eosinophils/HPF. Fourteen studies reported 358 
change in absolute eosinophil counts before and after therapy or by percentage changes from 359 
baseline in eosinophil density.23, 24, 26-30, 32, 33, 35, 37-40 One study used the EoE Histology Scoring 360 
System (EoE-HSS) to evaluate both severity and extent of eight features (eosinophil density, 361 
basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular 362 
spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis).38 363 
Four studies specified that histologic outcomes required changes at multiple esophageal levels 364 
(e.g. proximal and distal esophagus).19, 28, 30, 31  365 
 366 
Endoscopy Outcome Definitions 367 
Definitions of endoscopy outcomes for reported RCTs are summarized in Table 2 and for 368 
registered RCTs in Table 3. Several authors used non-validated changes in overall or global 369 
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endoscopic appearance with descriptions of classic EoE endoscopy findings (such as linear 370 
furrows, white exudates, and esophageal rings). Two studies used a visual analogue scale27, 33 371 
and four studies used the EoE Endoscopic Reference Score (EREFS).32, 36-38 The EREFS is the 372 
only endoscopic outcome instrument that has undergone inter- and intra-observer validation in 373 
both North American and European studies. The EREFS is also the most commonly used 374 
measurement tool for endoscopy outcomes in registered trials (4 studies, 40%). No consistently 375 
used thresholds for endoscopy scores were identified to determine endoscopic 376 
response/remission; rather, changes compared to baseline were commonly reported. 377 
 378 
Patient-Reported Outcome Definitions 379 
Definitions of patient-reported outcomes for reported RCTs are summarized in Table 2 and for 380 
registered RCTs in Table 3. Multiple different scoring systems, mostly non- or only partially 381 
validated, have been used to assess patient-reported response or remission. These include the 382 
Mayo Dysphagia Questionnaire24, 30, 34, the Dysphagia Symptom Questionnaire36, the EoE 383 
Activity Index (EEsAI)40, patient or physician global assessments of disease severity26, 32, 37, 40, 384 
the Dysphagia Score (also termed the Straumann Dysphagia Index)21-23, the EoE Clinical 385 
Symptom Score28, 31, the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS)20, and the 386 
Visual Dysphagia Questionnaire.27 As with endoscopy and histology endpoints, no uniformly 387 
applied thresholds for patient-reported remission or response have been identified although the 388 
complete absence of symptoms has been used by some authors to define remission. Health-389 
related quality of life was not specifically defined as a treatment endpoint in any of the currently 390 
published RCTs. 391 
 392 
Histology, Endoscopy, and Patient-Reported Placebo Rates 393 
Placebo rates in EoE RCTs are summarized in Figure 2 and Table 4, presented as either: (1) 394 
proportion of patients achieving response/remission defined by the original study authors; or (2) 395 
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percentage change in before and after treatment disease activity scores relative to the scale of 396 
scoring index when placebo response was reported as a continuous variable. The median 397 
histologic placebo response rate was 3.7% (range 0% to 31.6%). Two studies reported 398 
histologic placebo response or partial remission rates of >20%. Both studies used an eosinophil 399 
density cutoff of <20 eos/HPF (<65 eos/mm2 HPF).23, 33 The median histologic placebo 400 
remission rate was 0.0% (range 0% to 11.0%). Eight studies reported histologic placebo 401 
remission rates of 0%.20, 21, 23, 24, 28, 33, 39, 40 When assessed as a continuous measure relative to 402 
the scale of the measurement tool, endoscopy scores before and after placebo administration 403 
changed between -0.6% to -16%. Larger variances were evident when assessing patient-404 
reported placebo response (Figure 2): patient-reported scores before and after placebo 405 
administration varied between -28.6% to +36.6. The median symptomatic response rate was 406 
14.4% (range 8.6% to 77.8%); the median symptomatic remission rate was 26.2% (range 13.2% 407 
to 35.7%). 408 
409 
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Discussion 410 
Over the past two decades, clinical trials of therapeutic agents in EoE have evolved from 411 
retrospective case series with symptom-based outcomes to prospective, randomised, placebo-412 
controlled trials that include both valid patient-reported outcomes and objective measures such 413 
as histopathology and endoscopy.  In this systematic review of all reported and registered 414 
placebo-controlled trials of pharmacologic therapies for EoE, we describe the placebo response 415 
and summarise the outcome measures used in existing and planned RCTs. We found that 416 
histologic placebo response and remission rates in EoE trials are relatively low compared to 417 
RCTs in other gastrointestinal disorders, although there is greater variance in patient-reported 418 
placebo responses. We also highlight the significant heterogeneity in outcome measurement 419 
and outcome definitions used in current studies for histology, endoscopy, and patient-reported 420 
endpoints and there is no consensus on thresholds for defining response or remission.9 421 
Development of a COS that standardises outcome measurement and reporting in EoE RCTs is 422 
thus a priority. 423 
Potential determinants of the histologic placebo response in EoE RCTs include: 1) inclusion of 424 
patients with PPI-responsive EoE who derive both clinical and histologic benefits from 425 
concomitant PPI therapy41; 2) sampling of histologically normal mucosa in the context of patchy 426 
eosinophilic infiltration in EoE; 3) regression to the mean; and 4) spontaneous changes in 427 
disease activity in the natural history of EoE, possibly as a response to fluctuations in allergen 428 
or dietary exposures. Although symptomatic placebo rates in EoE tend to be lower than in other 429 
allergic and gastrointestinal disorders,42, 43 they still remain higher and more variable compared 430 
to histologic placebo response. Some EoE studies report greater than one third to one half of 431 
placebo patients achieving response or remission using patient-reported endpoints.23, 31, 36 432 
Symptomatic placebo rates may be influenced by dietary avoidance or modifications that reduce 433 
dysphagia or by endoscopic dilation at baseline if not precluded by the study entry criteria. 434 
However, this discrepancy between histologic and symptomatic placebo response also 435 
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underscores the discordance between patient-reported symptoms and objective measures of 436 
disease activity: in an international cohort study of 269 EoE patients, an Eosinophilic 437 
Esophagitis Activity Index (EEsAI) patient-reported outcome score of ≤15 points identified only 438 
67.2% of patients with endoscopic and histologic remission.44 439 
 440 
Additionally, histologic endpoints defined by eosinophil density may not closely correlate with 441 
patient-reported outcomes because dysphagia symptoms and risk of food impaction in EoE are 442 
driven primarily by complications of esophageal remodeling, rather than mucosal 443 
inflammation.45, 46 Histologic outcomes are assessed in nearly all EoE RCTs defined by either 444 
peak or mean eosinophil count per HPF. Although this paradigm is attractive because it 445 
provides a quantitative measure of inflammatory burden, several potential pitfalls exist. First, 446 
variability in results may be influenced by technical factors such as the cross-sectional area of 447 
the microscope manufacturer (correctable by using normalised density to eosinophils per mm2) 448 
and by sampling differences in the number and location of acquired biopsies.47-49 Second, 449 
mucosal biopsies may underestimate the full extent of histologic involvement in EoE given that 450 
eosinophilic infiltration is not confined to the superficial mucosa, eosinophil density does not 451 
necessarily correlate with eosinophil degranulation or function, and other histologic features 452 
such as basal cell hyperplasia, mast cell infiltration, and subepithelial fibrosis are not 453 
captured.50, 51  454 
 455 
To address some of these potential limitations of  peak eosinophil density as a measure of 456 
disease activity in EoE, Collins et al. have developed and validated an EoE Histology Scoring 457 
System (EoE-HSS), based on eight features (eosinophil density, basal zone hyperplasia, 458 
eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial 459 
alteration, dyskeratotic epithelial cells, and lamina propria fibrosis), graded and staged using a 460 
four point scale.52 Future studies should assess the responsiveness to change of this instrument 461 
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after a therapeutic intervention. Furthermore, adoption of blinded central reading to minimize 462 
observation bias at both enrolment and outcome ascertainment has gained traction in IBD. 463 
Although a single pathologist frequently evaluates histologic endpoints in current EoE RCTs, 464 
proper assessment inter- and intra-rater reliability using multiple blinded central readers for EoE 465 
histopathology endpoints is needed before this is routinely incorporated in clinical trials. 466 
 467 
Patient-reported outcomes will likely be an essential component of future registration trials in 468 
EoE based upon existing precedents in both ulcerative colitis and Crohn’s disease, whereby co- 469 
primary endpoints of PROs and objective assessment of inflammation (endoscopy) have been 470 
mandated. Although multiple scoring systems have been used to assess dysphagia symptoms 471 
in EoE RCTs most have not been validated in this disease. Two disease-specific, validated 472 
symptom scoring systems have recently been developed. The Dysphagia Symptom 473 
Questionnaire was developed from patient focus groups and primarily assesses frequency and 474 
intensity of dysphagia symptoms, with demonstrated responsiveness in an RCT of budesonide 475 
oral suspension.36 The EEsAI was prospectively developed and validated for use in adults with 476 
EoE and additionally captures food avoidance and behavioral modifications,53 a common source 477 
of reduced quality of life in EoE patients, particularly among those with previous food bolus 478 
impactions. Notwithstanding that eating behaviors such as careful mastication, prolonged meal 479 
times, and dietary restriction may not be adequately captured by assessment of dysphagia 480 
symptoms alone, both indices are candidate measurement tools for evaluating patient-reported 481 
outcomes in future RCTs. 482 
 483 
Endoscopic outcomes offer another potential objective treatment target in EoE RCTs. Earlier 484 
studies used non-validated global assessments of endoscopic appearance based on common 485 
EoE features. Development of the EoE Endoscopic Reference Score (EREFS), which 486 
incorporates both major (fixed rings, exudates, furrows, edema, stricture) and minor features 487 
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(crepe paper esophagus) has been an important advance.54 The items for the EREFS were 488 
identified through a literature review and a grading scheme was developed through consensus 489 
expert opinion. Internal validation, based on evaluation of a sampling of videos by 21 490 
endoscopists with diverse experience and practice patterns, demonstrated moderate to good 491 
interobserver reliability. The EREFS is the proposed endoscopic endpoint in four registered 492 
RCTs, but it still requires further external validation, particularly evaluating the role of central 493 
blinded endoscopy reading and comparison of video versus still-image endoscopic assessment 494 
on reliability performance characteristics.55 495 
 496 
Although histologic, endoscopic, and symptom-based outcomes have traditionally been used to 497 
assess EoE activity, there has been growing interest in quantifying and targeting esophageal 498 
distensibility as a measure of end organ remodeling. Functional lumen imaging probe (FLIP) 499 
uses impedance planimetry to quantify esophageal distention.6 Lower distensibility plateaus 500 
(DP) are associated with food bolus impaction and the need for esophageal dilation.45 In 501 
contrast, dietary and medical therapies have been demonstrated to improve DPs and this 502 
reduction correlates with better symptomatic outcomes.56 In a recent phase 2 placebo-controlled 503 
RCT, treatment with dupilumab, a humanised anti-IL-4Rα monoclonal antibody, improved 504 
esophageal distensibility and highlighted the potential of FLIP as a responsive biomarker to 505 
medical therapy.38  506 
 507 
Understanding outcome definitions in clinical trials is crucial for translating evidence-based 508 
research to clinical practice. Indeed, many of the newer EoE disease activity indices such as the 509 
EoEHSS, EEsAI, and EREFS have not yet been routinely incorporated in daily care. It is 510 
important for physicians to recognize that heterogeneity in outcome definitions used in clinical 511 
trials may influence interpretations of response to therapy. As the patient’s treatment goals are 512 
typically resolution of dysphagia symptoms, avoidance of food bolus impactions, prevention of 513 
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long-term disease complications, and ultimately, optimization of quality of life, these are 514 
parameters should be captured in outcome definitions for use in RCTs. Additionally, choosing 515 
appropriate histologic and endoscopic targets will help dictate therapeutic decisions in clinical 516 
practice: for example, targeting more stringent histologic endpoints (<5 eos/hpf vs. <15 517 
eos/hpf)57 or endoscopic resolution58 is associated with improved treatment response and 518 
symptom alleviation.  519 
 520 
Our study has some limitations. First, we included only placebo-controlled RCTs and a 521 
substantial proportion of the EoE literature is rooted in observational studies and non-controlled 522 
trials. Thus, there may be outcomes of interest that are not captured in this review. Second, we 523 
excluded trials of endoscopic therapies or dietary interventions. We restricted the inclusion 524 
specifically to RCTs investigating pharmacologic therapies because the focus of COS 525 
development will be primarily applicable to RCTs of novel therapeutic compounds. However, 526 
similar symptom-based and histologic outcomes are measured in both prospective and 527 
retrospective observational studies of dietary interventions in EoE, with heterogeneity in the 528 
defined thresholds for response and remission remaining an important challenge.59-63 A previous 529 
systematic review has also evaluated outcomes after endoscopic dilation for EoE64: efficacy was 530 
typically assessed using dysphagia scoring systems although there is an increased focus on 531 
safety outcomes, particularly with respect to esophageal perforation. Finally, we could not pool 532 
placebo rates to generate single point estimates. However, it is considered methodologically 533 
inappropriate to pool studies with such heterogeneity in outcome definitions, leading to a 534 
potentially biased point estimate that is not representative of the literature. Thus, we have 535 
presented the median as a measure of central tendency with ranges rather than a pooled point 536 
estimate. 537 
 538 
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The next steps in COS development have been outlined in the Core Outcome Measures in 539 
Effectiveness Trials (COMET) handbook.65 First, input from relevant stakeholders, including 540 
patients, health care providers, trialists, regulators, industry representatives, health policy-541 
makers, and researchers, will be sought. Next, relevant outcome domains will be defined. We 542 
propose that a similar framework to that presented in this review be considered, wherein a 543 
coprimary endpoint incorporating a patient-reported outcome measure and an objective 544 
histologic or endoscopic outcome in accordance with regulatory requirements be adopted. A 545 
consensus on specific outcome definitions and thresholds will be achieved through a multi-546 
round Delphi process that permits anonymized feedback to participants. Finally, the COS will be 547 
ratified and disseminated for implementation in future RCTs. 548 
 549 
CONCLUSION 550 
In conclusion, choosing appropriate treatment endpoints is crucial for clinical trial design. 551 
Outcomes should be relevant, valid, support regulatory and labelling claims, and correlate with 552 
meaningful changes in quality of life and disease course. In EoE, this translates to 553 
improvements in patient-reported symptoms, histologic burden of inflammation, and possibly 554 
reversal or prevention of fibrostenotic EoE complications. Although there has been significant 555 
progress in clinical trial research in EoE over the past two decades, we identify the substantial 556 
heterogeneity in outcome definitions in this field. Many instruments for EoE outcome 557 
assessment have only recently been developed and additional RCT data applying these 558 
instruments is required to adequately define response and remission cutoffs using anchor-559 
based methods. This systematic review serves as a conceptual framework for COS 560 
development in EoE. 561 
  562 
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Tables and Figures Legend  563 
Table 1. Baseline study characteristics 564 
Table 2. Histology, endoscopy, and symptom-based endpoints in published eosinophilic 565 
esophagitis placebo-controlled clinical trials 566 
Table 3. Histology, endoscopy, and symptom-based endpoints in registered eosinophilic 567 
esophagitis placebo-controlled clinical trials 568 
Table 4. Histology, endoscopy, and symptom-based placebo rates in published eosinophilic 569 
esophagitis placebo-controlled clinical trials 570 
 571 
Figure 1. Endpoint reporting in eosinophilic esophagitis placebo-controlled clinical trials, 572 
stratified by year of publication  573 
Figure 2. Box-and-whisker plots for histologic, endoscopic, and symptom-based placebo 574 
response and remission in eosinophilic esophagitis clinical trials. 575 
 576 
Supplemental File 1. Search strategy 577 
Supplemental Figure 1. PRISMA diagram 578 
Supplemental Table 1. Risk of bias assessment  579 
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Table 1. Baseline study characteristics 765 
 766 
 
n = 22 
Trial Participants (n) 
Total randomised participants 
Participants randomised to placebo 
 
1112 
410 
Trial Phase (n, %) 
Phase I 
Phase II 
Phase III 
 
2 (9.1) 
18 (81.8) 
2 (9.1) 
Trial Publication Year (n, %) 
2006-2010 
2011-2015 
2016-2017 
 
4 (18.2) 
9 (40.9) 
9 (40.9) 
Active Comparator (n, %) 
Corticosteroid 
Biologic Agent 
Other 
 
13 (59.1) 
6 (27.3) 
3 (13.6) † 
Trial Population (n, %) 
Pediatric/adolescent 
Adult 
Mixed 
 
5 (22.7) 
12 (54.5) 
5 (22.7) 
Patient Characteristics 
Mean participant age (years, SD) 
Mean disease duration (years, SD) 
Mean percentage of enrolled males (%, SD) 
Mean percentage of concurrent PPI (% SD) 
 
25.8 (13.6) 
4.1 (1.9) 
69.0 (14.1) 
57.0 (26.5) 
Follow-up (weeks, SD) 
Mean follow-up duration 
 
12.1 (10.7) 
 767 
†
 One trial of montelukast, one trial of prostaglandin D2 receptor CRTH2 antagonist, one trial of 768 
cromolyn sodium  769 
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Table 2. Histology, endoscopy, and symptom-based endpoints in published eosinophilic esophagitis placebo-controlled clinical trials 770 
 771 
Study 
Comparator and 
Time to Outcome 
Assessment Histology Endpoints Endoscopy Endpoints Symptom-Based Endpoints 
Konikoff 200619 Fluticasone 12 weeks 
Response: peak eosinophil 
count >1 and <24 eos per 400x 
HPF, in both proximal and 
distal esophagus 
Remission: peak eosinophil 
count <1 eosinophil in all 400x 
HPFs in both proximal and 
distal esophagus 
Presence of endoscopic 
furrowing, epithelial 
hyperplasia 
Presence of clinical symptoms 
(abdominal pain, vomiting, 
dysphagia) 
Dohil 201020 Budesonide 12 weeks 
Response: peak eosinophil 
count 7-9 eos/HPF 
Remission: peak eosinophil 
count 0-6 eos/HPF 
Change in epithelial histology, 
lamina propria histology, and 
lamina propria fibrosis 
Change in endoscopy scoring 
tool (mucosal pallor/reduced 
vasculature, linear 
furrows/mucosal thickening, 
white plaques, concentric 
rings/stricture, friability/“tissue-
paper” mucosa 
Change in symptom scoring 
tool (heartburn/regurgitation, 
abdominal pain, 
nausea/vomiting, 
anorexia/early satiety, 
dysphagia, symptom-induced 
nocturnal wakening, gastro-
intestinal bleeding) 
Straumann 2010a21 Budesonide 2 weeks 
Response: 5-20 eos/HPF 
Remission: <5 eos/HPF 
Change in endoscopic 
appearance (white exudates, 
red furrows, corrugated rings, 
solitary ring, crepe-paper sign, 
severe stenosis) 
Response: reduction in clinical 
symptom score ≥3 points 
compared to baseline using 
patient-reported outcome 
(frequency of dysphagia, 
intensity of dysphagia) 
Straumann 2010b22 Mepolizumab 34 weeks 
Response: peak eosinophil 
count <5 eos/HPF 
Change in endoscopic 
appearance (minor: fine 
nodules, fine whitish reticular 
structures, furrows; moderate: 
bright white scale- or plaque-
like structures, corrugated 
rings; or severe: mucosal 
lesions, fixed stenosis) 
Patient-reported Dysphagia 
Score (frequency of dysphagia, 
intensity of dysphagia, score 0-
9) 
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Study 
Comparator and 
Time to Outcome 
Assessment Histology Endpoints Endoscopy Endpoints Symptom-Based Endpoints 
Straumann 201123 Budesonide 50 weeks 
Remission: mean eosinophil 
count <5 eos/HPF (measured 
in 40 HPF) 
Partial remission: mean 
eosinophil count 5-20 eos/HPF 
Endoscopic ultrasound 
(thickness of mucosa, 
submucosa, muscularis 
propria) 
Patient-reported Dysphagia 
Score (frequency of dysphagia, 
intensity of dysphagia, score 0-
9) 
Alexander 201224 Fluticasone 6 weeks 
Complete response: >90% 
reduction in mean eosinophil 
count (from 5 HPF) 
Partial response: >50% 
reduction in mean eosinophil 
count 
Resolution of all endoscopic 
findings 
Complete response: answer of 
“no” to all questions by Mayo 
Dysphagia Questionnaire 
(MDQ-30) 
Partial response: decrease in 
severity of at least 2 levels 
Ghaffari 2012†25 Beclomethasone 8 weeks 
Tissue cytokine staining Not reported Not reported 
Spergel 201226 Reslizumab 15 weeks 
Percentage change in peak 
eosinophil count Not reported 
Change in Physician’s 
Eosinophilic Esophagitis 
Global Assessment (physical 
findings, vital signs, 
predominant eosinophilic 
esophagitis symptom 
assessment, patient’s 
symptom diary, dietary 
questions) 
Straumann 201327 
Prostaglandin D2 
receptor CRTH2 
antagonist 
8 weeks 
Reduction in esophageal 
eosinophil load (mean 
eosinophil count in 40 HPF) 
Global appearance of 
endoscopic appearance using 
10cm visual analogue scale 
Combination visual dysphagia 
questionnaire (VDQ 0-36), 
chest pain questionnaire (0-9) 
PRO 
Butz 201428 Fluticasone 6 months 
Complete remission: ≤1 
eos/HPF in proximal and distal 
esophagus 
Response: peak eosinophil 
count ≤6 eos/HPF, peak ≤14 
eos/HPF, mean eosinophil 
count ≤1 eos/HPF, mean 
eosinophil count ≤2 eos/HPF, 
decrease in eosinophil count 
≥90-95% 
Not reported 
EoE Symptom Score (vomiting, 
nausea, abdominal pain, 
dysphagia, heartburn, chest 
pain, regurgitation, food 
impactions, early satiety, poor 
appetite) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Ma et al.  Outcomes in EoE RCTs 
Page 35 of 42 
Study 
Comparator and 
Time to Outcome 
Assessment Histology Endpoints Endoscopy Endpoints Symptom-Based Endpoints 
Clayton 201429 Omalizumab 16 weeks 
Reduction in esophageal 
eosinophil content (maximum 
eos/HPF) 
Not reported Change in dysphagia score (0-6 Likert scale) 
Rothenberg 201430 
Anti-IL13 
(QAX576) 
6 months 
75% reduction in peak 
eosinophil count in proximal 
and distal esophagus 
Not reported 
Change in Mayo Dysphagia 
Questionnaire (eosinophilic 
esophagitis relevant questions, 
MDQ-30) 
Gupta 201531 Budesonide 12 weeks 
Response: peak eosinophil 
count ≤6 eos/HPF in all 
esophageal levels (composite 
outcome with clinical 
outcomes) 
Remission: peak eosinophil 
count ≤1 eos/HPF in all 
esophageal levels 
Not reported 
Symptom response: >50% 
reduction in Eosinophilic 
Esophagitis Clinical Symptom 
Score (EoE CSS) 
Symptom resolution: EoE CSS 
of 0 
Hirano 2016†32 
Anti-IL13 
(RPC4046) 
16 weeks 
Response: change in mean 
eosinophil count 
Change in EoE Endoscopic 
Reference Score (EREFS) 
Change in Daily Symptom 
Diary (DSD), EEsAI PRO, and 
Subject’s Global Assessment 
of Disease Severity 
Miehlke 201633 Budesonide 2 weeks 
Response: mean eosinophil 
count <65 eos/mm2 HPF 
Remission: mean eosinophil 
count <16 eos/mm2 HPF 
Change in endoscopic intensity 
score (white exudates, furrows, 
oedema, fixed rings, crepe 
paper sign, short segment 
stenosis, long-distance 
stenosis, 0-21) 
Global assessment of 
endoscopy appearance using 
100mm visual analogue scale 
Response: decrease in 
Dysphagia Score ≥3 
(frequency of dysphagia, 
intensity of dysphagia, score 0-
9) 
Alexander 201734 Montelukast 26 weeks Not reported Not reported 
Symptom remission: absence 
of dysphagia as measured by 
dysphagia frequency, severity, 
and food impaction questions 
from the Mayo Dysphagia 
Questionnaire, 2-week version 
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Study 
Comparator and 
Time to Outcome 
Assessment Histology Endpoints Endoscopy Endpoints Symptom-Based Endpoints 
Bhardwaj 201735 Beclomethasone 8 weeks 
Response: change in peak 
eosinophil count Not reported 
Symptom response: reduction 
in dysphagia, heartburn, 
abdominal pain, and other 
symptoms 
Dellon 201736 Budesonide 12 weeks Response: ≤6 eos/HPF 
Change in EoE Endoscopic 
Reference Score (EREFS) 
Change in Dysphagia 
Symptom Questionnaire (DSQ, 
0-84), ≥30% reduction in DSQ, 
≥50% reduction in DSQ 
Hirano 2017a†37 
Fluticasone (oral 
disintegrating 
tablet) 
8 weeks 
Change in median eosinophil 
count 
Improvement in endoscopic 
features as measured by the 
EoE Endoscopic Reference 
Score (EREFS) 
Improvement in Patient Global 
Assessment of Disease 
Severity (PatGA), EEsAI PRO 
Hirano 2017b†38 Dupilumab 12 weeks 
Change in overall peak 
eosinophil count, response 
(peak eosinophil <6 eos/hpf, 
<15 eos/hpf) 
Change in EoE Histological 
Scoring System 
Change in EoE Endoscopic 
Reference Score (EREFS) 
Response: reduction in 
Straumann Dysphagia Index 
≥3 points 
Response: reduction in EEsAI 
PRO by ≥40% 
Liebermann 2017†39 
Cromolyn sodium 
Follow-up not 
reported 
Change in peak eosinophil 
count 
Remission: complete resolution 
of eosinophilia 
Not reported 
Symptom reduction by 
symptom score (not further 
specified) 
Lucendo 2017†40 Budesonide 6 weeks 
Remission: clinicopathological 
remission (not further 
specified) 
Change in peak eosinophil 
count 
Rate of endoscopic 
normalization 
Change in total modified EEsAI 
endoscopic instrument score 
Remission: EEsAI-PRO ≤20 
Remission: resolution of 
dysphagia and pain during 
swallowing 
Time to first symptom 
resolution, change in Patient’s 
and Physician’s Global 
Assessment of EoE Activity 
Score 
 772 
†Results reported in abstract form 773 
EEsAI (Eosinophilic Esophagitis Activity Index), Eos (eosinophils), HPF (high power field), PRO (patient-reported outcome) 774 
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Table 3. Histology, endoscopy, and symptom-based endpoints in registered eosinophilic esophagitis placebo-controlled clinical trials 775 
 776 
Study 
(Clinicaltrials.gov  
Comparator and 
Time to Outcome 
Assessment Histology Endpoints Endoscopy Endpoints Symptom-Based Endpoints 
NCT02113267 
 
EudraCT 
2012-005842-39 
Mometasone 
8 weeks Not reported Not reported 
Change in Watson Dysphagia 
Scale Score (WDS) 
Change in EORTC QLQ-
OES18 Dysphagia Scale 
(eating scale and choking item) 
Global health/social functioning 
dimensions of SF-36 
NCT02605837 
Oral budesonide 
suspension 
16 weeks 
Response: peak eosinophil 
count ≤6 eos/HPF 
Change in peak eosinophil 
count, change in 
histopathologic epithelial 
features (by central reviewer) 
Change in EoE Endoscopic 
Reference Score (EREFS) 
Symptom response: ≥30% 
reduction in Dysphagia 
Symptom Questionnaire 
combined score 
Change in pain with swallowing 
NCT01702701 Montelukast 12 weeks 
Change in esophageal 
eosinophilia Not reported 
Improvement in Dysphagia 
Symptom Score 
NCT03191864 
 
EudraCT 
2016-004749-10 
APT-1011 
12 weeks 
Response: peak eosinophil 
count ≤6 eos/HPF (from 5-6 
biopsies from proximal and 
distal esophagus) 
Response: percentage of 
patients with peak eosinophil 
count <1 eos/HPF, <15 
eos/HPF 
Sustained response (histology 
response maintained at week 
12, 26, and 52) 
Change in EoE Endoscopic 
Reference Score (EREFS) 
Change in baseline Global EoE 
Symptom Score 
Change in number of 
dysphagia episodes at 
baseline 
NCT02873468 Fluticasone 8 weeks 
Change in eosinophilic 
infiltration (not further 
specified) 
Not reported Not reported 
NCT02371941 Cromolyn sodium 2 months 
Change in peak esophageal 
eosinophil count Not reported 
Change in symptom score by 
Pediatric Esophagitis Symptom 
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Study 
(Clinicaltrials.gov  
Comparator and 
Time to Outcome 
Assessment Histology Endpoints Endoscopy Endpoints Symptom-Based Endpoints 
Score 
NCT02019758 
Budesonide 
Fluticasone 
8 weeks 
Change in maximum 
eosinophil count 
Change in EoE Endoscopic 
Reference Score (EREFS) 
Change in Dysphagia 
Symptom Questionnaire 
NCT02493335 
Budesonide 
orodispersible 
tablet 
48 weeks 
Rate of patients with 
histological relapse Not reported 
Rate of patients free of 
treatment failure 
Rate of patients with clinical 
relapse 
NCT02736409 
Oral budesonide 
suspension 
36 weeks 
Change in peak eosinophil 
count 
Change in EoE Endoscopic 
Reference Score (EREFS) 
Change in Dysphagia 
Symptom Questionnaire 
EudraCT 
2005-006074-10 
Mepolizumab 
12 weeks 
Reduction in peak eosinophil 
count to <5 eos/HPF Not reported 
Frequency and severity of 
eosinophilic esophagitis-
related pain, regurgitation, 
vomiting, swallowing disorders, 
feeding difficulties 
 777 
  778 
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Table 4. Histology, endoscopy, and symptom-based placebo and active comparator rates in published eosinophilic esophagitis 779 
placebo-controlled clinical trials 780 
Study 
Placebo Histology 
Rate 
Active Comparator 
Histology Rate 
Placebo Endoscopy 
Rate 
Active Comparator 
Endoscopy Rate 
Placebo Symptom-
Based Rate 
Active Comparator 
Symptom-Based 
Rate 
Konikoff 
200619 
Response: 20.0% 
(3/15) 
Remission: 6.7% 
(1/15) 
Response: 55.0% 
(11/20) 
Remission: 50.0% 
(10/20) 
NR NR NR NR 
Dohil 
201020 
Response: 0.0% 
(0/9) 
Remission: 0.0% 
(0/9) 
 
∆ mean peak 
eosinophil count: -
18.3 eos/HPF 
Response: 6.7% 
(1/15) 
Remission: 86.7% 
(13/15) 
 
∆ mean peak 
eosinophil count: -
61.9 eos/HPF 
∆ mean endoscopy 
score: -16.0% (-
2.4/15) 
∆ mean endoscopy 
score: -20.7% (-
3.1/15) 
∆ mean symptom 
scoring tool: -6.4% (-
0.9/14) 
∆ mean symptom 
scoring tool: -16.4% 
(-2.3/14) 
Straumann 
2010a21 
Response: 0.0% 
(0/18) 
Remission: 11.1% 
(2/18) 
 
∆ mean eosinophil 
count: -5.8 eos/HPF 
Response: 16.7% 
(3/18) 
Remission: 72.2% 
(13/18) 
 
∆ mean eosinophil 
count: -62.7 eos/HPF 
NR NR 
∆ mean symptom 
score: -6.8% (-
0.61/9) 
∆ mean symptom 
score: -37.7% (-
3.39/9) 
Straumann 
2010b22 
∆ mean peak 
eosinophil count: -2.7 
eos/HPF 
∆ mean peak 
eosinophil count: -
39.4 eos/HPF 
NR NR NR NR 
Straumann 
201123 
Partial remission: 
28.6% (4/14) 
Remission: 0.0% 
(0/14) 
 
∆ mean eosinophil 
count: +64.3 
eos/HPF 
Partial remission: 
14.3% (2/14) 
Remission: 35.7% 
(5/14) 
 
∆ mean eosinophil 
count: +31.4 
eos/HPF 
NR NR 
Remission: 35.7% 
(5/14) 
 
∆ mean symptom 
score: +36.6% 
(+3.29/9) 
 
Remission: 64.3% 
(9/14) 
 
∆ mean symptom 
score: +16.7% 
(+1.5/9) 
Alexander 
201224 
Response: 0.0% 
(0/21) 
Response: 61.9% 
(13/21) 
Remission: 4.8% 
(1/21) 
Remission: 26.7% 
(4/15) 
Response: 33.3% 
(7/21) 
Response: 57.1% 
(12/21) 
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Study 
Placebo Histology 
Rate 
Active Comparator 
Histology Rate 
Placebo Endoscopy 
Rate 
Active Comparator 
Endoscopy Rate 
Placebo Symptom-
Based Rate 
Active Comparator 
Symptom-Based 
Rate 
Remission: 28.6% 
(6/21) 
Remission: 42.9% 
(9/21) 
Ghaffari 
2012†25 NR NR NR NR NR NR 
Spergel 
201226 NR NR NR NR 
∆ mean physician’s 
EoE global 
assessment score: -
11.4% (-1.14/10) 
∆ mean EoE 
predominant 
symptom 
assessment score: -
14.4% (-1.44/10) 
∆ mean physician’s 
EoE global 
assessment score: -
11.2% (-1.12/10) 
∆ mean EoE 
predominant 
symptom 
assessment score: -
12.8% (-1.28/10) 
Straumann 
201327 
∆ mean eosinophil 
count: -3.3 eos/HPF 
∆ mean eosinophil 
count: -41.6 eos/HPF 
∆ mean global 
endoscopy 
assessment score: -
0.6% (-0.06/10) 
∆ mean global 
endoscopy 
assessment score: -
3.6% (-0.36/10) 
∆ mean Visual 
Dysphagia 
Questionnaire: -
18.9% (-6.82/36) 
∆ mean Visual 
Dysphagia 
Questionnaire: -
15.8% (-5.71/36) 
Butz 201428 Remission: 0.0% (0/13) 
Remission: 65.2% 
(15/23) NR NR NR NR 
Clayton 
201429 
∆ mean eosinophil 
count: -4 eos/HPF 
∆ mean eosinophil 
count: -2 eos/HPF NR NR 
∆ dysphagia score: -
25.2% (-1.7/6) 
∆ dysphagia score: -
20.0% (-1.2/6) 
Rothenberg 
201430 
Response: 12.5% 
(1/8) 
Response: 40.0% 
(6/15) NR NR NR 
Response: 66.7% 
(10/15) 
Gupta 
201531 
Response: 5.6% 
(1/18) 
Response: 94.1% 
(16/17) NR NR 
Response: 77.8% 
(14/18) 
Remission: 33.3% 
(6/18) 
Response: 52.9% 
(9/17) 
Remission: 17.6% 
(3/17) 
Hirano 
2016*32 
∆ mean eosinophil 
count: -4.4  eos/HPF 
∆ mean eosinophil 
count: -99.9 eos/HPF 
∆ mean EREFS 
score: -4.5% (-
0.9/20) 
∆ mean EREFS 
score: -24.0% (-
4.8/20) 
∆ Daily Symptom 
Diary score: -7.6% (-
6.4/84) 
∆ Daily Symptom 
Diary score: -15.8% 
(-13.3/84) 
Miehlke 
201633 
Response: 31.6% 
(6/19) 
Remission: 0.0% 
(0/19) 
 
∆ mean eosinophil 
count: -30 eos/HPF 
Response: 94.7% 
(18/19) 
Remission: 89.5% 
(17/19) 
 
∆ mean eosinophil 
count: -287 eos/HPF 
Response: 26.3% 
(5/19) 
 
∆ mean total 
endoscopic 
abnormality score: -
3.3% (-0.7/21) 
Response: 57.9% 
(11/19) 
 
∆ mean total 
endoscopic 
abnormality score: -
16.8% (-3.4/21) 
∆ mean dysphagia 
score: -28.6% (-
2.0/9) 
∆ mean dysphagia 
score: -20.0% (-
1.8/9) 
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Study 
Placebo Histology 
Rate 
Active Comparator 
Histology Rate 
Placebo Endoscopy 
Rate 
Active Comparator 
Endoscopy Rate 
Placebo Symptom-
Based Rate 
Active Comparator 
Symptom-Based 
Rate 
Alexander 
201734 NR NR NR NR 
Remission: 23.8% 
(5/21) 
Remission: 40.0% 
(8/20) 
Bhardwaj 
201735 
∆ eosinophil count: -
25.3 eos/HPF 
∆ eosinophil count: -
50.7 eos/HPF NR NR NR NR 
Dellon 
201736 
Response: 2.6% 
(1/38) 
 
∆ peak eosinophil 
count: -17.3 eos/HPF 
Response: 38.8% 
(19/49) 
 
∆ peak eosinophil 
count: -117.0 
eos/HPF 
∆ mean EREFS 
score: 2.0% (0.4/20) 
∆ mean EREFS 
score: -19.0% (-3.8 
/20) 
Response: 44.7% 
(17/38) 
Remission: 13.2% 
(5/38) 
 
∆ mean Dysphagia 
Symptom 
Questionnaire: -8.9% 
(-7.5/84) 
Response: 69.4% 
(34/49) 
Remission: 20.4% 
(10/49) 
 
∆ mean Dysphagia 
Symptom 
Questionnaire: -
17.0% (-14.3/84) 
Hirano 
2017a†37 
∆ median eosinophil 
count: -136 cells/mm2 
HPF 
∆ median eosinophil 
count: -355 cells/mm2 
HPF 
∆ median EREFS 
score: -7.5% (-
1.5/20) 
∆ median EREFS 
score: -17.5% (-
3.5/20) 
∆ mean global 
assessment: -5.0% (-
0.5/10) 
∆ mean global 
assessment: -25.0% 
(-2.5/10) 
Hirano 
2017b†38 
Response: 0.0% 
(0/24) for both <6 and 
<15 eos/HPF 
 
∆ peak eosinophil 
count: -7.4 eos/HPF 
 
∆ Histology Scoring 
System (HSS) grade: 
+3.9% 
∆ Histology Scoring 
System (HSS) stage: 
-3.5% 
Response: 60.9% 
(14/23) for <6 
eos/HPF and 78.3% 
(18/23) for <15 
eos/HPF 
 
∆ peak eosinophil 
count: -94.1 eos/HPF 
 
∆ Histology Scoring 
System (HSS) grade: 
-64.2% 
∆ Histology Scoring 
System (HSS) stage: 
-58.1% 
∆ median EREFS 
score: -1.5% (-
0.3/20) 
∆ median EREFS 
score: -9.5% (-
1.9/20) 
Response: 12.5% 
(3/24) by Straumann 
Dysphagia Index, 
8.3% (2/24) by EEsAI 
PRO 
 
∆ Straumann 
Dysphagia Index: -
14.4% (-1.3/9) 
∆ EEsAI: -11.3% (-
11.3/100) 
Response: 39.1% 
(9/23) by Straumann 
Dysphagia Index, 
26.1% (6/23) by 
EEsAI PRO 
 
∆ Straumann 
Dysphagia Index: -
33.3% (-3.0/9) 
∆ EEsAI: -34.6% (-
34.6/100) 
Lieberman 
2017†39 
Remission: 0.0% 
(0/7) 
Remission: 11.1% 
(1/9) 
 
∆ mean peak 
eosinophil count: -
11.6 eos/HPF 
NR NR ∆ Symptom Score: -30.7% (-9.9/32.2) 
∆ Symptom Score: -
58.8% (-22.3/37.9) 
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Study 
Placebo Histology 
Rate 
Active Comparator 
Histology Rate 
Placebo Endoscopy 
Rate 
Active Comparator 
Endoscopy Rate 
Placebo Symptom-
Based Rate 
Active Comparator 
Symptom-Based 
Rate 
Lucendo 
2017†40 
Remission: 0.0% 
(0/29) 
 
∆ mean peak 
eosinophil count: -4 
eos/mm2 HPF 
Remission: 93.2% 
(55/59) 
 
∆ mean peak 
eosinophil count: -
226 eos/mm2 HPF 
Remission: 0.0% 
(0/29) 
Remission: 61.0% 
(36/59) 
Remission: 13.8% 
(4/29) 
 
∆ mean patient global 
assessment: -19.0% 
(-1.9/10) 
Remission: 59.3% 
(35/59) 
 
∆ mean patient global 
assessment: -38.0% 
(-3.8/10) 
 781 
For trials with multiple active comparators, results reported for highest administered dose 782 
†
 Results reported in abstract form 783 
EEsAI EoE Activity Index, HPF high power field, HSS Histology Scoring System, NR not reported, eos eosinophils, EREFS EoE 784 
Endoscopic Reference Scoring System 785 
∆ Change in pre- and post-treatment mean score in the placebo group, percentage change calibrated to scale of measurement 786 
instrument 787 
 788 
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Supplemental File 1. Search strategy 
MEDLINE 
1. random$.tw. 
2. factorial$.tw. 
3. (crossover$ or cross over$ or cross-over$).tw. 
4. placebo$.tw. 
5. single blind.mp. 
6. double blind.mp. 
7. triple blind.mp. 
8. (singl$ adj blind$).tw. 
9. (double$ adj blind$).tw. 
10. (tripl$ adj blind$).tw. 
11. assign$.tw. 
12. allocat$.tw. 
13. randomized controlled trial/ 
14. or/1-13 
15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or 
humans).ti.) 
16. 14 not 15 
17. eosinophilic esophagitis.mp. or exp eosinophilic esophagitis/ 
18. (eosinophil* and esophag*).mp.  
19. (eosinophil* and oesophag*).mp. 
20. or/17-19 
21. 16 and 20 
 
EMBASE 
1. random$.tw. 
2. factorial$.tw. 
3. (crossover$ or cross over$ or cross-over$).tw. 
4. placebo$.tw. 
5. single blind.mp. 
6. double blind.mp. 
7. triple blind.mp. 
8. (singl$ adj blind$).tw. 
9. (double$ adj blind$).tw. 
10. (tripl$ adj blind$).tw. 
11. assign$.tw. 
12. allocat$.tw. 
13. crossover procedure/ 
14. double blind procedure/ 
15. single blind procedure/ 
16. triple blind procedure/ 
17. randomized controlled trial/ 
18. or/1-17 
19. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or 
humans).ti.) 
20. 18 not 19 
21. eosinophilic esophagitis.mp. or exp eosinophilic esophagitis/ 
22. (eosinophil* and esophag*).mp.  
23. (eosinophil* and oesophag*).mp. 
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24. or/21-23 
25. 20 and 24 
 
Cochrane Central Register of Controlled Trials  
1. eosinophilic esophagitis 
2. eosinophilic oesophagitis 
3. or/1-2 
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Supplemental Figure 1. PRISMA diagram  
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Supplemental Table 1. Risk of bias assessment 
 
Study 
Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome data 
Selective 
reporting Other bias 
Konikoff 2006 Low risk Low risk Low risk Unclear risk Low risk Low risk Low risk 
Dohil 2010 Low risk Low risk Low risk Low risk Low risk High risk Low risk 
Straumann 2010a Low risk Low risk Low risk Unclear risk Low risk Low risk Low risk 
Straumann 2010b Low risk Low risk Low risk Unclear risk Low risk Low risk Low risk 
Straumann 2011 Low risk Low risk Low risk Unclear risk Low risk Low risk Low risk 
Alexander 2012 Low risk Low risk Unclear risk Low risk Unclear risk Low risk Low risk 
Spergel 2012 Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
Straumann 2013 Low risk Low risk Low risk Unclear risk Low risk Low risk Low risk 
Butz 2014 Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
Clayton 2014 Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk 
Rothenberg 2014 Low risk Unclear risk Low risk Low risk Low risk Low risk Unclear risk 
Gupta 2015 Unclear risk Low risk Unclear risk Low risk Low risk High risk Low risk 
Miehlke 2016 Low risk Low risk Low risk Unclear risk Low risk High risk Low risk 
Alexander 2017 Low risk Low risk Low risk Unclear risk Low risk Low risk Low risk 
Bhardwaj 2017 Unclear risk Low risk Unclear risk Unclear risk Low risk Low risk Low risk 
Dellon 2017 Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
 
